Recursion Pharmaceuticals RXRX and Schrodinger SDGR are pioneering the use of artificial intelligence (AI) in drug discovery ...

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

According to brokerage Jefferies, the average drug development cycle spans 8 to 10 years, with success rates below 10% and ...

Artificial intelligence and robotics are revolutionizing drug discovery by automating laboratory processes and enabling rapid ...

indicating significant advancements in their drug discovery capabilities. The company’s proprietary AI-driven platform, PEDAL, demonstrates a high accuracy rate of 92% in predicting tumor ...

Predictive Oncology Inc. has updated shareholders on its advancements in AI-driven drug discovery, specifically in biomarker discovery and drug repurposing, amid a growing biomarker discovery ...

Microsoft Scientific Discovery is an AI-powered research-focused platform designed for scientists, research institutions, and ...

SINGAPORE] Imagine a world where life-saving treatments are discovered not in decades, but in just a few years. Nanyang ...

Microsoft Corp. today announced the launch of Microsoft Discovery, a new enterprise-grade artificial intelligence platform ...

The Road Ahead From Singapore to Frankfurt, Leo International is building more than a business — it is building a bridge ...

GBAC “Quantum Healthcare 2025” board blueprint—$3.2 B QC drug-discovery market, 42 % CAGR, 50–70 % faster R&D cycles ...

"We are excited to be entering into this collaboration with Synfini to accelerate drug discovery around a publicly available high-value target,” said Helena Mancebo, CEO of Multispan. "By using ...